Skip to main content

Alcohol Use Disorder (AUD)

7
Pipeline Programs
9
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
3 programs
1
2
brexanolonePhase 2
suvorexantPhase 2
dexmedetomidinePhase 11 trial
Active Trials
NCT00205712Completed40Est. Oct 2007
Sage Therapeutics
Sage TherapeuticsMA - Cambridge
1 program
1
BrexanolonePhase 21 trial
Active Trials
NCT06580444Not Yet Recruiting40Est. Mar 2027
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
SuvorexantPhase 21 trial
Active Trials
NCT06679062Recruiting76Est. Jun 2026
Biocorp
BiocorpFrance - Issoire
1 program
1
TMP-301Phase 21 trial
Active Trials
NCT06648655Terminated110Est. Nov 2025
BioXcel Therapeutics
BioXcel TherapeuticsCT - New Haven
1 program
1
DexmedetomidinePhase 1
United Therapeutics
United TherapeuticsMD - Silver Spring
2 programs
DexmedetomidinePHASE_11 trial
BrexanolonePHASE_2
Active Trials
NCT06335407Recruiting10Est. May 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Recovery Navigator on an as needed basis up to 6 monthsN/A1 trial
Active Trials
NCT03059082Terminated47Est. Aug 2018
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
DCR-AUDPHASE_11 trial
Active Trials
NCT05021640Completed36Est. Dec 2022
Tempero Bio
Tempero BioCA - Oakland
1 program
TMP-301PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Alliance Pharmaceuticalsdexmedetomidine
Sage TherapeuticsBrexanolone
Angeles TherapeuticsSuvorexant
BiocorpTMP-301
United TherapeuticsDexmedetomidine
Novo NordiskDCR-AUD
Colorado TherapeuticsRecovery Navigator on an as needed basis up to 6 months

Clinical Trials (7)

Total enrollment: 359 patients across 7 trials

NCT00205712Alliance Pharmaceuticalsdexmedetomidine

Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids

Start: Feb 2003Est. completion: Oct 200740 patients
Phase 4Completed
NCT06580444Sage TherapeuticsBrexanolone

Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

Start: Jul 2025Est. completion: Mar 202740 patients
Phase 2Not Yet Recruiting
NCT06679062Angeles TherapeuticsSuvorexant

Suvorexant for Treatment of AUD and PTSD

Start: Jul 2025Est. completion: Jun 202676 patients
Phase 2Recruiting
NCT06648655BiocorpTMP-301

A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder

Start: Nov 2024Est. completion: Nov 2025110 patients
Phase 2Terminated
NCT06335407United TherapeuticsDexmedetomidine

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Start: Jul 2025Est. completion: May 202610 patients
Phase 1Recruiting
NCT05021640Novo NordiskDCR-AUD

Study of DCR-AUD in Healthy Volunteers

Start: Sep 2021Est. completion: Dec 202236 patients
Phase 1Completed
NCT03059082Colorado TherapeuticsRecovery Navigator on an as needed basis up to 6 months

A Critical Illness Recovery Navigator for Alcohol

Start: Dec 2016Est. completion: Aug 201847 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 359 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.